CAR-T cell therapy has emerged as a revolutionary treatment for certain hematological malignancies, particularly relapsed/refractory B-cell malignancies, in the USA.
The FDA has approved six CAR-T cell products targeting CD19 and BCMA antigens for the treatment of acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).


Approved CAR-T Cell Products

Tisagenlecleucel (Kymriah, Novartis) and Brexucabtagene autoleucel (Tecartus, Gilead) for relapsed/refractory B-cell precursor ALL Axicabtagene ciloleucel (Yescarta, Gilead) and Lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) for relapsed/refractory large B-cell lymphoma Idecabtagene vicleucel (Abecma, Bristol Myers Squibb/Bluebird Bio) and Ciltacabtagene autoleucel (Carvykti, Legend/Janssen) for relapsed/refractory multiple myeloma.

These CAR-T cell therapies have demonstrated remarkable efficacy, with high response rates and durable remissions in patients who had exhausted other treatment options.



What is the life expectancy after CAR T-cell therapy?

The success rate and life expectancy following CAR-T therapy can vary due to multiple factors. Notably, some of the earliest recipients have experienced remarkable outcomes. For example, the first patient treated with CAR-T in 2010 has been cancer-free for 14 years, and Emily Whitehead, the first pediatric CAR-T patient treated in 2012, is thriving and studying at university today in 2024.
Source: Dr. Carl June lecture at the 6th EBMT


CAR-T cell therapy cost in USA

Below are several commercialized CAR-T cell products in the USA and their prices, as of 2024.

Swipe table to see all columns
Company Product Price Target Approved time
NOVATIS Kymriah 475000 US dollars CD19 2017.08
Gilead Kite Yescarta 373000 US dollars CD19 2017.10
Gilead Kite Tecartus 373000 US dollars CD19 2020.07
Bristol-Myers Squibb Breyanzi 410300 US dollars CD19 2021.03
Blue Bird Abecma 419500 US dollars BCMA 2021.03
Nanjing Legend Biotech Carvikti 465000 US dollars BCMA 2022.02





CAR-T cell therapy in Israel >>